小分子抑制剂作为向致癌融合蛋白的治疗剂:现状和临床情况
Yichao Kong1,2, Caihong Jiang1,2, Guifeng Wei1,2
1School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
Molecules (Basel, Switzerland)
|June 28, 2023
概括
小分子抑制剂在向致癌融合蛋白,驱动癌症方面表现有前途. 这篇评论详细介绍了癌症药物发现的机制,挑战和临床进展.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于染色体重组而产生的致癌融合蛋白质是癌症发展的关键驱动因素.
- 这些融合蛋白代表了新型癌症治疗的关键标.
- 小分子抑制剂提供了一种有针对性的方法来对抗具有这些特定分子变化的癌症.
研究的目的:
- 提供针对瘤性融合蛋白的小分子抑制剂的全面审查.
- 阐明这些向治疗的作用机制和临床进展.
- 为医疗界提供信息,加快针对融合蛋白驱动癌症的药物发现.
主要方法:
- 关于小分子抑制剂和瘤性融合蛋白的当前研究的文献综述.
- 分析针对融合蛋白的理由,作用机制和挑战.
- 临床试验数据和现场进展的总结.
主要成果:
- 小分子抑制剂在选择性向致癌融合蛋白中表现出显著的潜力.
- 针对特定的融合蛋白的各种抑制剂已经显示出有前途的临床结果.
- 挑战包括抵抗机制和非目标效应,需要进一步研究.
结论:
- 小分子抑制剂是一种可行的,不断发展的治疗策略,用于对抗由融合蛋白驱动的癌症.
- 持续的研究和开发对于克服挑战和优化治疗疗效至关重要.
- 本综述为推进有针对性的癌症治疗发现计划提供了宝贵的资源.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targets for Drug Action: Overview
6.5K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.5K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575


